Skip to main content

Market Overview

Why Coherus Biosciences 15% Dip Provides An Opportunity To Buy

Why Coherus Biosciences 15% Dip Provides An Opportunity To Buy

Shares of Coherus Biosciences Inc (NASDAQ: CHRS) were trading down more than 15 percent on Monday following news that the Patent Trials and Appeals Board didn't institute their Intellectual Property Rights (IPR) '166 over Abbvie’s Humira.

Amid the price action, Citi analyst Mohit Bansal advised investors in a note that the institution of the ‘166 patent IPR isn't core to Citi’s thesis regarding Coherus and that investors should “buy on weakness.”

Bansal maintained a Buy rating and $36 price target for the stock.

"While this is being seen as a negative for CHRS, we note that our checks with patent experts did not suggest this patent was a key obstacle against a Humira biosimilar," said Bansal.

At time of writing, shares of Coherus were trading down around 11.5 percent at $24.90.

Latest Ratings for CHRS

Feb 2021HC Wainwright & Co.MaintainsBuy
Nov 2020MizuhoMaintainsBuy
Nov 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for CHRS
View the Latest Analyst Ratings


Related Articles (CHRS)

View Comments and Join the Discussion!

Posted-In: Citi Mohit BansalAnalyst Color Analyst Ratings Best of Benzinga

Latest Ratings

OSPNSidoti & Co.Upgrades39.0
PLTSidoti & Co.Upgrades48.0
LRCXArgus ResearchMaintains725.0
ROSTLoop CapitalMaintains145.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at